Key result
Nebivolol and telmisartan were equally effective in reducing blood pressure, decreasing left ventricular mass index, and increasing midwall fractional shortening over 3 months.
Why the study?
Does nebivolol compared to telmisartan improve left ventricular mass and midwall mechanics in patients with mild-to-moderate hypertension?
RCT (n=40)
randomized
Does nebivolol compared to telmisartan improve left ventricular mass and midwall mechanics in patients with mild-to-moderate hypertension?
Nebivolol and telmisartan are equally effective in reducing blood pressure, decreasing left ventricular mass, and increasing midwall fractional shortening in mild-to-moderate hypertension.
Answers are grounded in this paper and cite their sources.
Either nebivolol or telmisartan may be used for LV mass reduction in hypertension; confirms comparable effects on remodeling.
BACKGROUND: The aim of this study was to compare the effects of nebivolol and telmisartan on left ventricular mass (LVM) and midwall mechanics in mild-to-moderate hypertension. METHODS: A total of 40 patients with mild-to-moderate hypertension were randomized to receive either nebivolol (2.5 to 5.0 mg/day) or telmisartan (40 to 80 mg/day) to achieve a target diastolic blood pressure of <90 mm Hg. Blood pressure (BP) was measured with sphygmomanometry, and LVM and midwall fractional shortening (mFS) were estimated by two-dimensionally guided M-mode echocardiography at baseline and at 3-month follow-up. RESULTS: Age, sex distribution, and baseline SBP and DBP and heart rate were similar in the two groups. Both nebivolol and telmisartan reduced systolic (156 +/- 7 v 124 +/- 8 mm Hg, P < .01, and 153 +/- 5 v 120 +/- 7 mm Hg, P < .01, respectively) and DBP (99 +/- 4 v 80 +/- 2 mm Hg, P < .01 and 98 +/- 2 v 80 +/-2 mm Hg, P < .01, respectively) and increased mFS (16% +/- 2% v 19% +/- 2%, P < .01, and 15% +/- 2% v 18% +/- 2%, P < .01, respectively). The LVM indices decreased significantly with both nebivolol (98 +/- 16 v 84 +/- 13 g/m(2), P < .01) and telmisartan (97 +/- 13 v 83 +/- 8 g/m(2), P < .01). We found that mFS was inversely related to DBP in the nebivolol but not in the telmisartan group. CONCLUSIONS: In mild-to-moderate hypertension, nebivolol and telmisartan are equally effective in reducing BP and increasing mFS. There may be differences between nebivolol and telmisartan regarding the mechanism of increase in mFS.
No takes yet. Share an insight, caveat, or question.
Fountoulaki et al. (2005) conducted an RCT in mild-to-moderate hypertension (n=40). Nebivolol vs. Telmisartan (40 to 80 mg/day) was evaluated on Left ventricular mass (LVM) and midwall fractional shortening (mFS). Nebivolol and telmisartan were equally effective in reducing blood pressure, decreasing left ventricular mass index, and increasing midwall fractional shortening over 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: